Income From Financial Royalty Assets was Royalty Pharma’s largest product and service line in fiscal 2025, bringing in $2.26B of $2.38B (95%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Income From Financial Royalty Assets | $2.13B | $2.20B | $2.15B | $2.26B | ||||
| Financial Royalty Assets | — | — | — | — | ||||
| Revenue From Intangible Royalty Assets | — | — | — | — | ||||
| Intangible Royalty Assets | — | — | — | — | ||||
| Other Royalty Income & Revenues | $112.12M | $156.80M | $114.15M | $117.04M | ||||
| Other Royalty Income | — | — | — | — | ||||
| Royalty Income, Other | — | — | — | — | ||||
| Total | $2.24B | $2.35B | $2.26B | $2.38B |
Royalty Pharma brought in $2.38B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 5.1% from $2.26B in fiscal 2024. Income From Financial Royalty Assets was the largest at $2.26B (95.1%), ahead of Other Royalty Income & Revenues at $117.04M (4.9%).
Compared with fiscal 2024, Income From Financial Royalty Assets grew 5.2% to $2.26B and Other Royalty Income & Revenues grew 2.5% to $117.04M. From fiscal 2022 to 2025, combined revenue from these lines grew from $2.24B to $2.38B, a compound annual growth rate of 2.1%. Income From Financial Royalty Assets' share held steady at about 95.1%.
Royalty Pharma (RPRX) reports its revenue by product and service. In fiscal 2025, Income From Financial Royalty Assets was its largest product and service line, bringing in $2.26B (95.1% of the total), followed by Other Royalty Income & Revenues at $117.04M (4.9%).
Income From Financial Royalty Assets was Royalty Pharma's largest product and service line in fiscal 2025, bringing in $2.26B, or 95.1% of the $2.38B total across its two product and service lines.
Income From Financial Royalty Assets grew faster than Other Royalty Income & Revenues in fiscal 2025, up 5.2% from $2.15B to $2.26B. Other Royalty Income & Revenues grew 2.5% to $117.04M.
Every figure comes from Royalty Pharma's annual financial filings, as reported. Each line keeps the name Royalty Pharma gives it, and years follow its fiscal calendar.
Royalty Pharma's revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.